STELARA®

Therapeutic Area: Immunology

Drug Type: Biologic

Molecule: Ustekinumab

Clinical Phase: Approved

Pipeline Status: Active

Indication: Plaque Psoriasis (Pediatric & Adult), Psoriatic Arthritis, Crohn’s Disease, and Ulcerative Colitis.

Mechanism of Action: Stelara (ustekinumab) operates through a sophisticated dual-inhibition mechanism that distinguishes it from many other biologics in the immunology sector. As a fully human IgG1κ monoclonal antibody, it is engineered to target and bind with high affinity to the p40 protein subunit, a common structural component shared by two critical pro-inflammatory cytokines: Interleukin-12 (IL-12) and Interleukin-23 (IL-23). By neutralizing this p40 subunit, Stelara effectively prevents these cytokines from interacting with the IL-12Rβ1 receptor complex found on the surface of immune cells such as T-cells and Natural Killer (NK) cells. This blockade interrupts the intracellular signaling cascades, specifically the Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) pathways, which are essential for the differentiation and activation of Th1 and Th17 cell populations. Consequently, the drug inhibits the downstream production of inflammatory mediators like interferon-gamma (IFN-γ) and IL-17A, thereby reducing the chronic epithelial inflammation and abnormal skin cell proliferation characteristic of Crohn’s disease, ulcerative colitis, and plaque psoriasis. This broad upstream intervention remains a pivotal strategy in achieving long-term clinical remission for patients with multi-faceted autoimmune pathologies.